Wegovy is a registered trademark of Novo Nordisk A/S. It is an FDA-approved prescription medicine. A licensed clinician must evaluate each patient and determine whether prescribing it is appropriate.
Important safety information: Wegovy has a boxed warning about the risk of thyroid C-cell tumors. It should not be used by anyone with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. Important serious risks include pancreatitis, gallbladder problems, low blood sugar with certain diabetes medicines, acute kidney injury related to dehydration, serious allergic reactions, severe stomach problems, increased heart rate, and suicidal behavior or thinking. Read the complete official Wegovy Prescribing Information and Medication Guide, including the boxed warning, indications, contraindications, warnings, and adverse reactions. A clinician should weigh potential benefits and risks for the individual.
Does Medicare cover Wegovy? The accurate answer is that coverage can depend on the prescribed use, the person's plan, and eligibility for a specific Medicare pathway. It is not automatically covered for every Medicare beneficiary or every use.
Body Good may provide coverage support, including assistance with benefit checks and requested paperwork. Medicare, the Part D plan, or the applicable program makes all eligibility, approval, and payment decisions.
This page is general information, not medical advice. Talk to a licensed clinician about your situation.
Part D coverage for a coverable use
Federal law generally excludes drugs used only for weight loss from the basic Medicare Part D benefit. That does not mean every prescription for a medicine also used in weight management is excluded in every circumstance.
Wegovy also has an FDA-approved indication to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. The Centers for Medicare & Medicaid Services guidance identifies this as an example of a use that can be covered through Part D.
The plan can still apply its current formulary procedures, prior authorization criteria, quantity limits, and pharmacy network rules. A prescription and a covered indication do not by themselves guarantee that a particular claim will be paid.
Ask the Part D plan whether the exact prescribed use is covered, what documentation is required, and which pharmacy should fill it. The plan's written decision controls.
The Medicare GLP-1 Bridge is a separate route
CMS created a temporary Medicare GLP-1 Bridge running from July 1, 2026, through December 31, 2027. It is designed for certain Part D beneficiaries who meet defined clinical and plan criteria for eligible GLP-1 medicines.
According to the CMS information for Part D plans, eligibility is not universal. It depends on factors that include enrollment in a participating type of Part D plan, clinical criteria set by CMS, and whether the prescription is already coverable through the basic Part D benefit.
The manufacturer's official Wegovy cost and coverage page describes a $50 monthly copay for eligible beneficiaries under the Bridge. That amount applies only when all program terms are met. It is not a price promise for every Medicare member.
If the prescribed use is already coverable under the person's Part D benefit, CMS says the beneficiary does not qualify for Bridge coverage of that prescription. The existing Part D route remains responsible for its coverable use.
Questions to ask the Medicare plan
Call the number on the member card and ask:
- Is this prescription being reviewed under the basic Part D benefit or the Medicare GLP-1 Bridge?
- What indication and clinical documentation are required?
- Is prior authorization required, and who receives the request?
- Which pharmacies participate or are preferred?
- What copay or coinsurance applies under the correct route?
- How can I request a written coverage decision or appeal an adverse decision?
Keep notes from the call. Record the date, representative, and reference number. If the answer is unclear, ask where the rule appears in the plan's current Evidence of Coverage or CMS guidance.
Coverage information is an estimate until the plan reviews the claim and any requested clinical information. Body Good can assist with administrative steps, but it cannot control the result.
Savings cards and Medicare
Manufacturer commercial savings cards usually exclude beneficiaries enrolled in federal health care programs. Novo Nordisk's current Wegovy savings terms state that government beneficiaries are excluded from the commercial savings offer.
That commercial offer is different from the Medicare GLP-1 Bridge. Do not assume a savings-card advertisement applies to a Medicare prescription. Review the terms for the correct program and payment route.
A self-pay purchase made outside Medicare may not count toward the Part D deductible or out-of-pocket spending. Ask the plan before choosing that route. Also ask the pharmacy to explain whether it is processing the prescription through Part D, the Bridge, or cash payment.
Body Good fees are not Medicare drug costs
Body Good's prices are service fees for the program described during intake. They are not the price of medication and are not a quote for any individual. Eligibility is determined by a clinician.
The medication cost is separate and may be charged by a pharmacy or another authorized provider. Medicare coverage of a prescription does not establish coverage of Body Good's service fee. Confirm each charge and benefit separately.
Body Good may assist with benefit checks, plan-requested documentation, and pharmacy routing. Approval and payment are determined by the plan or program, not by Body Good.
This website is an informational and pricing overview. It takes no payment, collects no protected health information, and runs no intake form. Intake and checkout occur on joinbodygood.com.
Frequently asked questions
Does Medicare cover Wegovy for weight loss alone?
Basic Part D generally excludes drugs when used only for weight loss. Some beneficiaries may qualify for the separate temporary Medicare GLP-1 Bridge if they meet all CMS criteria. Eligibility is not automatic.
Can Part D cover Wegovy for cardiovascular risk reduction?
CMS identifies its FDA-approved cardiovascular risk-reduction use as a potentially coverable Part D indication. The plan applies its terms and makes the coverage decision after reviewing the prescription and required information.
Can Body Good tell me whether Medicare will approve it?
Body Good can assist with checking benefits and submitting information requested by the plan. It cannot guarantee eligibility or approval. Begin the secure intake to provide information for clinical review.
Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Body Good is not affiliated with, endorsed by, sponsored by, or authorized by Eli Lilly and Company or Novo Nordisk A/S. All trademarks are the property of their respective owners.